PTC Therapeutics Inc logo

PTC Therapeutics Inc

PTCT
Healthcare|Biotechnology|USA
$84.85
-4.70 (-5.25%)

Upcoming Data Readouts (3)

Dec 2026
Est. completion
NACTNNB1
Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene)
NCT07614126n=7
Dec 2027
Est. completion
P3Friedreich Ataxia
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
NCT05515536n=130
Feb 2031
Est. completion
P3Phenylketonuria
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
NCT06302348n=56

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P3
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
NCT05166161
Mar 2024
P1
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
NCT03605550
May 2023
P2
A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants
NCT04903288

Recent Press Releases